Table 2.
Characteristics of trials (or parts of trials) eligible for comparison B
| Trial | Years of accrual | De novo or relapsed M1? | Treatment | Control | Number of patients accrued | ||
|---|---|---|---|---|---|---|---|
| Radiotherapy | Docetaxel |
Abiraterone/ Prednisone |
ADT | ||||
| B1 Radiotherapy + abiraterone + ADT versus abiraterone + ADT | |||||||
| PEACE-1B1 (NCT01957436) | 2013-2018* | De novo | 74Gy, 37 fractions within 7 to 8 wk | - | Abiraterone 1000mg/day Prednisone 10mg/day |
ADT LHRH agonist or antagonist or orchiectomy | 229 |
| B2 Radiotherapy + docetaxel + ADT versus docetaxel + ADT | |||||||
| STAMPEDE B2[11] (Arm H vs Arm A) |
2015-2016 | De novo | 36Gy, 6 fractions over 6 weeks or 55Gy, 20 fractions over 4 wk |
According to local protocol or 75mg/m2 every 3 wk for 6 cycles | - | ADT LHRH agonist or antagonist or orchiectomy | 367 |
| PEACE-1B2 (NCT01957436) |
2013-2018* | De novo | 74Gy, 37 fractions within 7 to 8 wk | 75mg/m2 every 3 wk for 6 cycles | - | ADT LHRH agonist or antagonist or orchiectomy | 355 |
| B3 Radiotherapy + abiraterone + docetaxel + ADT versus abiraterone + docetaxel + ADT | |||||||
| PEACE-1B3 (NCT01957436) | 2013-2018* | De novo | 74Gy, 37 fractions within 7 to 8 wk | 75mg/m2 every 3 wk for 6 cycles | Abiraterone 1000mg/day Prednisone 10mg/day |
ADT LHRH agonist or antagonist or orchiectomy | 355 |
ADT = androgen deprivation therapy; LHRH = luteinising hormone-releasing hormone. *PEACE-1 closed to accrual between submission and acceptance of the manuscript